Enovis (NYSE:ENOV) Given New $42.00 Price Target at BTIG Research

Posted by Brian Himes on Nov 5th, 2026

Enovis (NYSE:ENOV – Get Free Report) had its price objective boosted by investment analysts at BTIG Research from $36.00 to $42.00 in a research report issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research‘s target price indicates a potential upside of 51.30% from the company’s previous close.

ENOV has been the subject of a number of other research reports. BMO Capital Markets set a $27.00 price objective on shares of Enovis in a research note on Tuesday, September 1st. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Citigroup restated a “market outperform” rating on shares of Enovis in a research note on Wednesday, September 2nd. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Finally, Canaccord Genuity Group dropped their price target on Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, August 17th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Check Out Our Latest Analysis on Enovis

Enovis Stock Performance

ENOV traded up $3.34 during trading on Thursday, hitting $27.76. The company’s stock had a trading volume of 2,854,814 shares, compared to its average volume of 1,257,060. The business’s 50 day simple moving average is $19.79 and its 200-day simple moving average is $23.05. The firm has a market cap of $1.60 billion, a PE ratio of -1.43 and a beta of 1.31. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. Enovis has a one year low of $16.70 and a one year high of $32.41.

Enovis (NYSE:ENOV – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.11. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The firm had revenue of $558.73 million during the quarter, compared to analysts’ expectations of $557.12 million. During the same quarter last year, the business posted $0.75 earnings per share. The firm’s revenue was up 1.8% on a year-over-year basis. As a group, sell-side analysts predict that Enovis will post 3.15 EPS for the current fiscal year.

Insider Activity at Enovis

In related news, insider Oliver Engert bought 5,140 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were bought at an average price of $19.46 per share, with a total value of $100,024.40. Following the completion of the transaction, the insider directly owned 61,238 shares of the company’s stock, valued at $1,191,691.48. This represents a 9.16% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Damien Mcdonald bought 13,035 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was bought at an average price of $19.15 per share, with a total value of $249,620.25. Following the acquisition, the chief executive officer directly owned 247,077 shares in the company, valued at $4,731,524.55. The trade was a 5.57% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 23,293 shares of company stock worth $449,599. Insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ENOV. Bank of America Corp DE purchased a new stake in Enovis during the 2nd quarter worth about $11,502,000. First National Bank of Omaha acquired a new position in shares of Enovis during the second quarter worth about $1,250,000. Legal & General Group Plc purchased a new stake in shares of Enovis during the second quarter worth approximately $2,753,000. Jupiter Topco LLC acquired a new stake in Enovis in the second quarter valued at approximately $2,346,000. Finally, Man Group plc purchased a new position in Enovis in the second quarter worth approximately $8,711,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis News Summary

Here are the key news stories impacting Enovis this week:

Positive Sentiment: Enovis reported adjusted earnings of $0.88 per share, above analyst estimates of $0.76–$0.77 and up from $0.75 a year earlier. The earnings beat is a key catalyst for the stock’s advance. Article: Enovis Q3 Earnings and Revenues Beat Estimates
Positive Sentiment: The company announced a $200 million share buyback, which could support demand for shares and signals a commitment to returning capital to shareholders. Article: Enovis announces a $200 million equity buyback
Neutral Sentiment: Quarterly revenue was $558.73 million, slightly above analyst expectations of $557.12 million and 1.8% higher year over year. The modest growth and largely in-line revenue provide a less powerful catalyst than the earnings beat. Article: Enovis announces third-quarter 2026 results

About Enovis

(Get Free Report)

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.